Ketorolac 30 mg is the primary injectable strength of Toradol, widely used for short‑term management of acute moderate to severe pain. Administered intramuscularly (IM) or intravenously (IV), this formulation provides a rapid onset and a moderate duration of action, making it suitable for postoperative pain, trauma care, and emergency settings where fast, reliable analgesia is essential.
As a potent NSAID, ketorolac delivers strong non‑opioid pain relief but is intended only for brief use due to its safety profile. This page offers an overview of how the 30 mg injection works, where it is typically used, and how it compares with higher‑dose options such as Ketorolac 60 mg. For a broader look at injectable therapy, visit the Toradol injection page.
Ketorolac 30 mg Injection is the primary injectable formulation of ketorolac tromethamine, a potent nonsteroidal anti-inflammatory drug (NSAID) used for short-term management of acute moderate to severe pain. This dosage is administered either intramuscularly (IM) or intravenously (IV), depending on clinical needs. The 30 mg strength is considered the standard Toradol injection dose, widely used in hospitals, emergency departments, and postoperative recovery units. It provides rapid systemic absorption, predictable onset, and strong analgesic effect, making it suitable for situations where fast, reliable pain control is essential.
Ketorolac 30 mg works by inhibiting prostaglandin synthesis, reducing inflammation and decreasing pain receptor sensitivity. This mechanism is typical of NSAIDs but more potent in ketorolac, which is why it is reserved for short-term use. The injectable form produces a fast onset because the medication enters systemic circulation quickly, especially when administered intravenously. Despite its strong effect, ketorolac is used only briefly due to gastrointestinal and renal risks associated with prolonged prostaglandin inhibition. This section provides an overview of the 30 mg injectable form rather than treatment recommendations.
Ketorolac 30 mg Injection is widely used for short-term management of acute moderate to severe pain in clinical environments where rapid stabilization is required. It is commonly administered after surgical procedures to control postoperative pain, especially when strong non-opioid analgesia is needed. The fast onset of the injectable form makes it suitable for immediate pain control during the early recovery phase.
The 30 mg dose is also used for trauma-related pain, such as fractures, severe sprains, or musculoskeletal injuries, where rapid analgesia is essential. Because the onset is faster than oral formulations, ketorolac injections are often chosen when immediate relief is required. More information on pain-related use cases is available on the Toradol for pain page.
In some clinical settings, ketorolac injections may be used for acute migraine episodes when rapid non-opioid analgesia is needed. Additional details can be found on the Toradol for migraine page.
The 30 mg strength is considered the “standard dose” because it provides a strong balance of rapid onset, predictable duration, and broad clinical applicability. It is strong enough for most acute pain scenarios but not as intense as the 60 mg injection, which is typically reserved for specific high-intensity situations. This makes 30 mg the most commonly used and widely recognized Toradol injection dose.
Ketorolac 30 mg can be administered intramuscularly (IM) or intravenously (IV), depending on the clinical situation. IM administration delivers the medication into muscle tissue, where it is absorbed rapidly into the bloodstream. This route provides fast analgesia and is commonly used in urgent care, postoperative recovery, and trauma settings when IV access is not required.
IV administration provides the fastest onset because the medication enters systemic circulation immediately. This makes IV ketorolac the preferred option in emergency departments, surgical recovery units, and situations where rapid stabilization is essential. A detailed comparison of IM and IV routes is available on the Toradol IM vs IV page.
Clinically, IM is chosen for convenience and rapid effect without the need for IV lines, while IV is selected for maximum speed and precision. Both routes offer strong analgesia, but IV onset is noticeably faster. The choice depends on urgency, patient condition, and clinical workflow.
Ketorolac 30 mg Injection has a fast onset when administered intramuscularly and an even faster onset when given intravenously. IV administration delivers the medication directly into the bloodstream, producing near-immediate analgesic effects. IM injections are slightly slower but still provide rapid relief due to efficient absorption through muscle tissue.
The injectable form works significantly faster than oral tablets because it bypasses the digestive system and first-pass metabolism. This makes ketorolac injections ideal for acute pain scenarios where rapid stabilization is required. More information about onset differences is available on the Toradol onset & duration page.
Factors influencing onset include route of administration, patient circulation status, and the severity of the underlying condition. Regardless of these variables, ketorolac 30 mg consistently provides fast, reliable analgesia in clinical settings.
Ketorolac 30 mg provides a moderate duration of analgesia, long enough to manage acute pain episodes but not intended for prolonged therapy. The duration is similar across IM and IV routes because ketorolac’s elimination profile remains consistent regardless of how it is administered.
The effect is intentionally limited due to safety considerations. Prolonged prostaglandin inhibition increases the risk of gastrointestinal irritation, ulcers, bleeding, and kidney stress. For this reason, ketorolac injections are used only short-term and are not suitable for chronic pain management.
The moderate duration makes Ketorolac 30 mg ideal for rapid stabilization followed by transition to oral therapy if continued analgesia is needed.
Ketorolac injections are available in several strengths, with 20 mg, 30 mg, and 60 mg being the most common. The 30 mg dose is considered the “gold standard” because it provides a strong balance of rapid onset, predictable duration, and broad clinical applicability. It is widely used in hospitals for postoperative pain, trauma, and emergency care.
The Ketorolac 20 mg dose is an intermediate option, offering strong analgesia with a slightly lower systemic load. It is used when clinicians want rapid relief but prefer a more conservative dose than 30 mg.
The Ketorolac 60 mg injection is typically used in situations requiring a higher single administration, often in specific high-intensity pain scenarios. It provides strong analgesia but is used cautiously due to increased systemic exposure.
The 30 mg dose remains the most common because it is strong enough for the majority of acute pain cases while maintaining a safety profile appropriate for short-term use. It offers the best balance between potency, onset, and clinical flexibility, making it the preferred injectable strength in most settings.
Ketorolac 30 mg Injection is chosen when rapid, high‑intensity analgesia is required. Because the injectable form enters systemic circulation quickly—especially when given intravenously—it is used in hospitals, emergency departments, and postoperative recovery units. It is preferred for acute pain that requires fast stabilization, such as trauma, surgical pain, or severe flare‑ups where oral medications would act too slowly.
Toradol Oral, described in detail on the Toradol oral page, is typically used after the acute phase has been controlled. Tablets have a slower onset because they must be absorbed through the gastrointestinal tract, but they provide a convenient way to maintain analgesia once the patient is stable and no longer needs injectable therapy.
The onset of injections is fast, while the onset of tablets is moderate. Duration is similar across both forms, but injections are reserved for short-term use due to their potency and systemic impact. The common clinical sequence is “injection → tablets,” where Ketorolac 30 mg provides rapid initial relief, followed by oral ketorolac for continued short-term pain control.
Ketorolac 30 mg Injection shares the same side‑effect profile as other injectable ketorolac formulations, but its potency makes these effects more pronounced than with standard NSAIDs. Common side effects include nausea, stomach discomfort, dizziness, and headache. Because ketorolac strongly inhibits prostaglandins, it may irritate the gastrointestinal lining, increasing the risk of stomach pain or indigestion.
More serious risks include gastrointestinal bleeding, ulceration, and kidney stress. Prostaglandins help protect the stomach and support renal blood flow, so strong inhibition can lead to complications when ketorolac is used for extended periods. These risks apply to all injectable strengths, including 30 mg, and are the primary reason ketorolac is restricted to short-term use.
IM and IV administration have similar systemic side effects, but local reactions may differ. IM injections can occasionally cause soreness or discomfort at the injection site, while IV administration may cause vein irritation in some patients. However, these local effects are generally mild compared with the systemic risks associated with prolonged prostaglandin inhibition.
Because ketorolac is a high-potency NSAID, limiting the duration of therapy is essential. Short-term use helps reduce the likelihood of gastrointestinal and renal complications, ensuring that the medication provides strong analgesia without unnecessary risk.
Ketorolac 30 mg Injection is contraindicated in individuals with active gastrointestinal ulcers, recent GI bleeding, or a history of perforation, as its strong prostaglandin inhibition can worsen these conditions. It is also avoided in patients with severe kidney impairment, since reduced renal blood flow may further compromise kidney function.
Age-related considerations apply as well. Older adults may be more susceptible to gastrointestinal and renal side effects, and clinicians often use caution when prescribing ketorolac in this population. The medication is intended strictly for short-term use, and prolonged therapy is avoided to reduce the likelihood of serious complications.
Combining ketorolac with other NSAIDs is generally avoided because it increases the risk of gastrointestinal irritation, kidney stress, and bleeding. Caution is also required in individuals with bleeding disorders, dehydration, cardiovascular risk factors, or conditions that may worsen with prostaglandin inhibition.
| Parameter | Value |
|---|---|
| Form | Injection |
| Dosage | 30 mg |
| Route | IM / IV |
| Onset | Fast |
| Duration | Moderate |
| Use | Acute pain |
Ketorolac 30 mg is the standard injectable strength used in hospitals for acute pain management. It provides a fast onset and moderate duration, making it suitable for postoperative pain, trauma, and emergency care. Its potency and rapid action make it a preferred non-opioid option for short-term stabilization.
| Dosage | Route | Onset | Duration | Where Used |
|---|---|---|---|---|
| 20 mg | IM / IV | Fast | Moderate | Acute pain |
| 30 mg | IM / IV | Fast | Moderate | Standard dose |
| 60 mg | IM | Fast | Moderate | Severe pain |
All three injectable strengths provide fast onset and moderate duration, but they differ in intensity and clinical use. The 20 mg dose is an intermediate option, the 30 mg dose is the standard hospital strength, and the 60 mg dose is reserved for situations requiring a higher single administration. Each strength is selected based on the severity of pain and clinical judgment.
| Form | Onset | Duration |
|---|---|---|
| Injection | Fast | Moderate |
| Nasal | Fast | Moderate |
| Oral | Moderate | Moderate |
Toradol injections provide the fastest onset because they enter systemic circulation quickly. Nasal spray also acts rapidly by bypassing the digestive system. Oral tablets have a slower onset due to gastrointestinal absorption, but all forms share a similar moderate duration. These differences guide clinical decisions when selecting the appropriate form for acute pain management.